Bargain price Pradaxa secured reimbursement in New Zealand
This article was originally published in Scrip
Executive Summary
Boehringer Ingelheim offered to provide its warfarin replacement blood thinner Pradaxa (dabigatran) to authorities in New Zealand at half its US price and then offered a further discount, according to Pharmac, New Zealand's pharmaceutical management agency. The price was an influential factor in the agency's decision to reimburse it, says the agency.